CD2-HE120-100μg / 询价
CD2-HE120-500μg / 询价
CD2-HE120-500μgx2 / 询价
- 客服电话
- 技术支持
Human CD20/MS4A1 Protein
Recombinant Human CD20/MS4A1 Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus.It contains Ile141-Ser188 [Accession | P11836-1].
The protein has a predicted MW of 16.8 kDa same as Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
Less than 1EU per μg by the LAL method.
Supplied as 0.22μm filtered solution in 20mM PB, 10% Glycerol, 0.4M Urea, 1mM GSH, 0.1mM GSSG (pH 7.0).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human CD20 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Human CD20, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 4.4μg/ml determined by ELISA.
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7
(1)Ma D , Mcdevitt M R , Barendswaard E , et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66.
(2)Jager U , Fridrik M , Zeitlinger M , et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
